Pharmacodiagnostics and targeted therapies - A rational approach for individualizing medical anticancer therapy in breast cancer

Oncologist

Volumn 12, Issue 4, 2007, Pages 397-405

  Jørgensen, Jan Trøst ^a   Nielsen, Kirsten Vang ^a   Ejlertsen, Bent ^b  

^a AGILENT TECHNOLOGIES   (United States)

^b Rigshospitalet   (Denmark)

Author keywords

Breast cancer; HER 2; Hormone receptor; Predictive biomarker; Targeted therapy; TOP2A

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; ANTIESTROGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ALOPECIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LEUKOPENIA; NAUSEA AND VOMITING; ONCOGENE NEU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS; TUMOR BIOPSY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34247868929     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-397     Document Type: Review

References (50)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
2. le Grand A, Hogerzeil HV, Haaijer-Ruskamp FM. Intervention research in rational use of drugs: A review. Health Policy Plan 1999;14:89-102.
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
4. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Bhargava R, Chen B, Klimstra DS et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006;106:1857-1862.
7. Potti A, Ganti AK, Foster H et al. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 2004;24:333-337.
8. Olsen KE, Knudsen H, Rasmussen BB et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35-42.
9. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-7490.
10. Umemura S, Osamura RY. Utility of immunohistochemistry in breast cancer practice. Breast Cancer 2004;11:334-338.
11. Weier HU, Greulich-Bode KM, Ito Y et al. FISH in cancer diagnosis and prognostication: From cause to course of disease. Expert Rev Mol Diagn 2002;2:109-119.
12. Denoux Y, Arnould L, Fiche M et al. [HER2 gene amplification assay: Is CISH an alternative to FISH?] Ann Pathol 2003;23:617-622. French.
13. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol 2004;31(suppl 3):21-27.
14. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005;12:73-81.
15. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. The Oncologist 2003;8:335-341.
16. Korenman SG. Estrogen receptor assay in human breast cancer. J Natl Cancer Inst 1975;55:543-545.
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
18. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28(suppl 3):13-19.
19. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in earlystage breast cancer. The Oncologist 2004;9:606-616.
20. Carlson RW, Moench SJ, Hammond ME et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(suppl 3):S1-S22; quiz S23-S24.
21. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
22. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
24. Slamon D, Eierman W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S1. Available at http://209.196.53.174/2005/, (www.sabcs.org). Accessed March 25, 2007.
25. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist 2004;9(suppl 3):10-15.
26. Nelson HM, Dolder CR. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006;40:261-269.
27. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639.
28. Spector NL, Blackwell K, Hurley J et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. J Clin Oncol 2006;24(suppl 18):3S.
29. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
30. Nagata Y, Lan K-H, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.
31. Gomez HL, Chavez MA, Doval DC et al. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):S63.
32. Köstler WJ, Hudelist G, Rabitsch W et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol 2006;132:9-18.
33. Kim C, Bryant J, Horne Z et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 2005;94(suppl 1):S6.
34. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-6763.
35. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54(suppl 4):1-7.
36. Tewey KM, Rowe TC, Yang L et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-468.
37. Praga C, Bergh J, Bliss J et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-4191.
38. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709.
39. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502-3508.
40. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.
41. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116.
42. MacGrogan G, Rudolph P, Mascarel Id I et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 2003;89:666-671.
43. Park K, Kim J, Lim S et al. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39:631-634.
44. Martin-Richard M, Munoz M, Albanell J et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004;66:388-394.
45. Press MF, Mass RD, Zhou JY et al. Association of topoisomerase II-alpha (TOP2A) gene amplification with responsiveness to anthracycline-containing chemotherapy among women with metastatic breast cancer entered in Herceptin H0648g pivotal clinical trial. J Clin Oncol 2005;23(suppl):##.
46. Tanner MM, Isola J, Wiklund T et al. Topoisomerase IIα gene amplification predicts favorable treatment response of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu amplified breast cancer: Results from the randomized Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24:1-9.
47. O'Malley FP, Chia S, Tu D et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). J Clin Oncol 2006;24(suppl):##.
48. Knoop AS, Knudsen H, Balslev E et al. TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG trial (DBCG89D). J Clin Oncol 2006;24 (suppl):##.
49. Di Leo A. Topoisomerase II Alpha: Ready for Primetime? ASCO Annual Meeting 2006. Available at http://www.asco.org/portal/site/ASCO. Accessed July 5, 2006.
50. U.S. Food and Drug Administration (FDA). Drug-Diagnostic Co-Development Concept Paper. Draft. Rockville, MD: FDA, April 2005. Available at: http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf. Accessed March 25, 2007.